Israeli Ministry Approves Phase 2/3 Trial of Silexion's SIL204 for Locally Advanced Pancreatic Cancer

Silexion Therapeutics has received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for its SIL204 treatment in locally advanced pancreatic cancer. This marks a significant regulatory milestone and advances the company into clinical-stage development. SIL204 targets KRAS mutations present in over 90% of pancreatic cancers and has shown strong positive preclinical results and successful completion of toxicology studies. The company expects to initiate human clinical trials in the second quarter of 2026.